2023-04-22 08:28:22
Image d’illustration
© PEAKSTOCK / SCIENCE PHOTO LIBRARY
It is a revolution for the 600,000 to 1 million French people affected by vitiligo, this autoimmune disease causing depigmentation of the skin: the Opzelura cream (developed by the American biotech Incyte) received authorization on Thursday of placing on the market of the European Medicines Agency.
“It should be in pharmacies in the coming months”announces Martine Carré, the president of the French Vitiligo Association, who points out that the terms of reimbursement remain to be specified.
A first step
“It’s the end of the therapeutic desert”rejoices Professor Julien Seneschal, head of the inflammatory and autoimmune dermatology unit at the Bordeaux University Hospital, who participated in the two main international studies which concluded that the treatment was effective on “31% of patients”. A first step, for Professor Seneschal, “which paves the way for other innovative treatments”.
1682166530
#vitiligo #drug #approved #European #Medicines #Agency
